title: Trastuzumab: possible publication bias.
authors.affiliation: Pharmaceutical Management Agency (PHARMAC), Wellington 6143, New Zealand. scott.metcalfe@pharmac.govt.nz
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Carl
authors.initials: C
authors.lastname: Burgess
authors.forename: George
authors.initials: G
authors.lastname: Laking
authors.forename: Jackie
authors.initials: J
authors.lastname: Evans
authors.forename: Susan
authors.initials: S
authors.lastname: Wells
authors.forename: Steffan
authors.initials: S
authors.lastname: Crausaz
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008958:Models, Molecular; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab